SCHEMBL30135932

SCHEMBL30135932

O=C1CCC(c2ccc(N3CCC4(CC3)CN(C3CCN(NC(=O)OCc5ccccc5)CC3)C4)c(F)c2)C(=O)N1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 10/20 0.35
DDB1 Q16531 9/20 0.35
IKZF3 Q9UKT9 5/20 0.35
MGAT2 Q10469 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KDM1A O60341 2/20 0.33
MAOA P21397 2/20 0.33
MAOB P27338 2/20 0.33
KDM1B Q8NB78 2/20 0.33
RCOR1 Q9UKL0 2/20 0.33
DRD2 P14416 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
GRM5 P41594 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30981387 0.88 CRBN (0.35) CRBNDDB1IKZF3MGAT2DRD2
SCHEMBL30981383 0.88 CRBN (0.35) CRBNDDB1IKZF3MGAT2DRD2
SCHEMBL30136013 0.84 DDB1 (0.36) CRBNDDB1HRH3ALDH1A1CYP3A4
SCHEMBL30981145 0.84 ENPP2 (0.39) CRBNDDB1IKZF3KDM1AMAOB
SCHEMBL30136014 0.81 POLB (0.42) LMNAALDH1A1
SCHEMBL30923234 0.80 DDB1 (0.45) CRBNDDB1HRH3ALDH1A1
SCHEMBL30136008 0.79 CRBN (0.46) CRBNDDB1IKZF3
SCHEMBL25823260 0.79 CRBN (0.40) CRBNDDB1HRH3
SCHEMBL30965622 0.78 ENPP2 (0.37) CRBNDDB1IKZF3KDM1AMAOB
SCHEMBL30135903 0.76 ALDH1A1 (0.40) CRBNDDB1KDM1AMAOBDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed
EP-4157849-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2023-04-05 EP disclosed
WO-2023018238-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 CRBN 2136/4885DDB1 132/4885IKZF3 1904/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 CRBN 2496/4885DDB1 77/4885IKZF3 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.